Market Cap : 2.67 B | Enterprise Value : 2.23 B | PE Ratio : 26.79 | PB Ratio : 5.09 |
---|
NAS:CORT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:CORT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Corcept Therapeutics's interest expense for the three months ended in Dec. 2020 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2020 was $0.0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Corcept Therapeutics's Operating Income for the three months ended in Dec. 2020 was $ 30.5 Mil. Corcept Therapeutics's Interest Expense for the three months ended in Dec. 2020 was $ 0.0 Mil. GuruFocus does not calculate Corcept Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2020 was 0 (Mar. 2020 ) + 0 (Jun. 2020 ) + 0 (Sep. 2020 ) + 0 (Dec. 2020 ) = $0.0 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Corcept Therapeutics's Interest Expense for the three months ended in Dec. 2020 was $0.0 Mil. Its Operating Income for the three months ended in Dec. 2020 was $30.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2020 was $0.5 Mil.
Corcept Therapeutics's Interest Coverage for the quarter that ended in Dec. 2020 is calculated as
GuruFocus does not calculate Corcept Therapeutics's interest coverage with the available data. |
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies interest coverage is at least 5. Corcept Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
No Headline